Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

ge healthcare s.r.l., miláno itÁlie - 9600 makroagregÁty lidskÉho albuminu - kit pro radiofarmakum - 2mg - technecium-(99mtc) makroagregÁty lidskÉho albuminu

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 10645 sumatriptan-sukcinÁt - dispergovatelná tableta - 100mg - sumatriptan

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 10645 sumatriptan-sukcinÁt - dispergovatelná tableta - 50mg - sumatriptan

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

unigene uk ltd. - recombinant salmon calcitonin - hypercalcemia; osteitis deformans; bone resorption - vápníková homeostáza - kalcitonin je indikován pro:prevenci akutní ztráty kostní tkáně způsobené náhlou imobilizací, např. u pacientů s recentosteoporotic fracturespaget je diseasehypercalcaemia malignity.

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

dolorgiet gmbh & co.kg, sankt augustin array - 1593 ibuprofen - potahovaná tableta - 800mg - ibuprofen

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

curium austria gmbh, hausmannstaetten array - 19174 fluorcholinium-(18f)-chlorid - injekční roztok - 1gbq/ml - fluorcholin-(18f)

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 10645 sumatriptan-sukcinÁt - injekční roztok v zásobní vložce - 6mg - sumatriptan

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

zaklady farmaceutyczne polpharma sa, starogard gdański array - 1387 monohydrÁt sodnÉ soli sulfacetamidu - oční kapky, roztok v jednodávkovém obalu - 100mg/ml - sulfacetamid

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autologní cd34+ buněk obohacený populace, která obsahuje krvetvorné kmenové buňky transduced s lentiglobin bb305 lentiviral vektor kódující beta--t87q-globin gene - beta-talasémie - other hematological agents - zynteglo je indikován pro léčbu pacientů od 12 let a starší s závislá na transfuzi β talasemie (tdt), kteří nemají β0/β0 genotyp, pro koho hematopoetických kmenových buněk (hsc) transplantaci je vhodné, ale lidský leukocytární antigen (hla)-uzavřeno související dárce hsc není k dispozici.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.